A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes
Biological effects of GIP The Gastric Inhibitory Polypeptide (GIP), isolated for the first time from porcine small intestine in 1971 [27], was named as GIP on the basis of its ability to inhibit gastric hydrochloric acid secretion [28]
Qua , cc t bo gan s c Gluthion bo v v h tr
Cardiorenal syndrome (CRS) involves the interplay between hemodynamic, inflammatory, and neurohumoral abnormalities to produce worsening heart and kidney function
But it means its even more important to plan what happens after weight lossdietary change and physical activity remain essential. Ongoing research is exploring maintenance-phase strategies, lower dosing and alternative compounds that might preserve metabolic benefits while minimizing side effects